INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 42h ago
HOUSE PTR2h ago
SEC 13F2h ago
ROBINHOOD CHAIN2h ago
SEC FORM 4/Grant or awardVerified data

Mao Li reported LEGN

Director · Legend Biotech Corp · Ordinary Shares

Side
A
Value
—
Shares
21.0K
Price
—
Executed
Sep 24, 2026
Disclosed
Sep 28, 2026
Disclosure timeline4 days from execution to publication · legal deadline 2 business days
Sep 24 executedSep 28, 2026 disclosed

LEGN · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
17/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Grant or award — administrative, little informational value

  • Relative size+9 / 25

No reported dollar value · 47.3% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · LEGN

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    40
    SD
    Sanders Corazon (Corsee) D.Director
    LEGNLegend Biotech Corp
    Open-market sale
    		SELL$259K
    27.4K sh
    		Sep 29, 2026Oct 1, 2026
    traded Sep 29, 2026
    		+2dSEC FORM 4

    Evidence

    21
    HJ
    Heyman Tomas J.Director
    LEGNLegend Biotech Corp
    Grant or award
    		A—
    21.0K sh
    		Sep 24, 2026Sep 28, 2026
    traded Sep 24, 2026
    		+4dSEC FORM 4

    Evidence

    17
    SD
    Sanders Corazon (Corsee) D.Director
    LEGNLegend Biotech Corp
    Grant or award
    		A—
    21.0K sh
    		Sep 24, 2026Sep 28, 2026
    traded Sep 24, 2026
    		+4dSEC FORM 4

    Evidence

    21
    SP
    Salovey PeterDirector
    LEGNLegend Biotech Corp
    Grant or award
    		A—
    28.3K sh
    		Sep 24, 2026Sep 28, 2026
    traded Sep 24, 2026
    		+4dSEC FORM 4

    Evidence

    13
    CJ
    Casey Patrick JohnDirector
    LEGNLegend Biotech Corp
    Grant or award
    		A—
    21.0K sh
    		Sep 24, 2026Sep 28, 2026
    traded Sep 24, 2026
    		+4dSEC FORM 4

    Evidence

    17
    JX
    Ji Darren XiaohuiDirector
    LEGNLegend Biotech Corp
    Grant or award
    		A—
    28.3K sh
    		Sep 24, 2026Sep 28, 2026
    traded Sep 24, 2026
    		+4dSEC FORM 4

    Evidence

    9
    SE
    Santos Carlos EChief Financial Officer
    LEGNLegend Biotech Corp
    Grant or award
    		A—
    19.7K sh
    		Sep 21, 2026Sep 23, 2026
    traded Sep 21, 2026
    		+2dSEC FORM 4

    Evidence

    34
    SE
    Santos Carlos EChief Financial Officer
    LEGNLegend Biotech Corp
    Open-market sale
    		SELL$50K
    5,430 sh
    		Sep 21, 2026Sep 23, 2026
    traded Sep 21, 2026
    		+2dSEC FORM 4

    Evidence

    9
    ZI
    Zhang IngridChief Executive Officer
    LEGNLegend Biotech Corp
    Grant or award
    		A—
    1.13M sh
    		Sep 15, 2026Sep 16, 2026
    traded Sep 15, 2026
    		+1dSEC FORM 4

    Evidence

    33
    CJ
    Casey Patrick JohnDirector
    LEGNLegend Biotech Corp
    Open-market sale
    		SELL$89K
    6,000 sh
    		Jun 30, 2026Jul 2, 2026
    traded Jun 30, 2026
    		+2dSEC FORM 4

    Evidence

    25
    HY
    Huang YingDirector, Chief Executive Officer
    LEGNLegend Biotech Corp
    Open-market sale
    		SELL$82K
    5,566 sh
    		Jun 25, 2026Jun 29, 2026
    traded Jun 25, 2026
    		+4dSEC FORM 4

    Evidence

    24
    HY
    Huang YingDirector, Chief Executive Officer
    LEGNLegend Biotech Corp
    Open-market sale
    		SELL$87K
    9,936 sh
    		Mar 25, 2026Mar 27, 2026
    traded Mar 25, 2026
    		+2dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0002106809-26-000005
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Sep 24, 2026
    Published
    Sep 28, 2026
    Ingested by INSIDER
    Nov 5, 02:14 UTC
    Last re-read
    Nov 5, 02:14 UTC

    Extracted facts

    Filer
    Mao Li
    Role
    Director
    Transaction
    Grant or awardAs filed: “A”
    Asset
    Legend Biotech Corp
    Ticker
    LEGN
    Shares
    21.0K
    Price per share
    $0
    Execution date (reported)
    Sep 24, 2026
    Owned after transaction
    65.3K shares
    Days from execution to publication
    4

    What this establishes

    Mao Li filed this Form 4 reporting a grant or award of LEGN on Sep 24, 2026. It became public on Sep 28, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director
    Mao Licik:0002106809
    Issuer
    Legend Biotech Corpcik:0001801198

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.